Skip to content

Clinical trials

Myocardial Infarction trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myocardial Infarction Country / region: China Clear all

121 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20021
20031
20051
20061
20072
20085
20092
20106
20114
20123
20135
20144
20157
20164
20176
201810
20195
20208
20216
20226
20239
20244
20258
202610

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed46
Unknown status38
Recruiting18
Not yet recruiting8
Active, not recruiting5
Terminated3
Enrolling by invitation3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Beijing Anzhen Hospital7
Chinese Academy of Medical Sciences, Fuwai Hospital7
Chinese PLA General Hospital7
Xijing Hospital6
Medtronic Vascular5
Qilu Hospital of Shandong University5
Shanghai 10th People's Hospital5
Novartis Pharmaceuticals4
Second Affiliated Hospital, Zhejiang University, School of Medicine4
AstraZeneca3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myocardial Infarction121
Coronary Artery Disease22
Cardiovascular Diseases18
Stroke16
Myocardial Ischemia13
ST Elevation Myocardial Infarction10
Acute Coronary Syndrome9
Angina, Unstable6
Coronary Disease6
Angina Pectoris5

Trials

Showing 51 to 75 of 121. Each trial links to its page on Pharma Observatory.

21 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.